Validation of the Friedewald Formula in Patients with Metabolic Syndrome
Cholesterol · 06.02.2014 · 2014 · 1-5
DOI: 10.1155/2014/261878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cholesterol, erschienen am 06.02.2014. Verfasst von José Knopfholz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, Prado Velho, 1155 Curitiba, PR, Brazil. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Pontifícia Universidade Católica do Paraná.
Abstract (Originalsprache)
Currently, the Friedewald formula (FF) is the main method for evaluating low-density lipoprotein cholesterol (LDL-c). Recently, many limitations have emerged regarding its use, including patients with triglyceride levels ≥400 mg/dL, diabetes mellitus, and kidney or hepatic chronic diseases. We analyzed the use of the FF in patients with metabolic syndrome. We selected patients with known metabolic syndrome that fulfilled the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report and excluded patients with triglyceride levels ≥400 mg/dL and chronic liver and/or kidney disease. Using direct assays, we measured total cholesterol, high-density lipoprotein cholesterol, triglycerides, and LDL-c. Then, LDL-c was estimated using the FF and compared with the LDL-c by direct assay. The sample size was 135 patients. Using the FF, the mean LDL-c value was 124.4 ± 42.1 mg/dL; it was 125.1 ± 38.5 mg/dL by direct assay. The correlation coefficient between these two methods was 0.89, with statistical significance ( P value < 0.001 ) . There were no significant differences between the patients with triglyceride levels >150 mg/dL ( P = 0.618 ) . In conclusion, FF is a good method for estimating LDL-c in patients with metabolic syndrome.
Autor:innen und Institutionen
- Pontifícia Universidade Católica do Paraná, Rua Imaculada Conceição, Prado Velho, 1155 Curitiba, PR, Brazil.
ORCID-Profile: Larissa Streisky
Förderung
- Pontifícia Universidade Católica do Paraná
Zitieren
APA
Knopfholz, J., Disserol, C. C., Pierin, A. J., Schirr, F. L., Streisky, L., Takito, L. L., Massucheto Ledesma, P., Faria-Neto, J. R., Olandoski, M., da Cunha, C. L., & Bandeira, A. M. (2014). Validation of the Friedewald Formula in Patients with Metabolic Syndrome. Cholesterol, 2014, 1-5. https://doi.org/10.1155/2014/261878
Vancouver
Knopfholz J, Disserol CC, Pierin AJ, Schirr FL, Streisky L, Takito LL, et al. Validation of the Friedewald Formula in Patients with Metabolic Syndrome. Cholesterol. 2014;2014:1-5. doi:10.1155/2014/261878
BibTeX
@article{Knopfholz2014,
author = {Knopfholz, José and Disserol, Caio César Diniz and Pierin, Andressa Jardim and Schirr, Fernanda Letícia and Streisky, Larissa and Takito, Lilian Lumi and Massucheto Ledesma, Patrícia and Faria-Neto, José Rocha and Olandoski, Marcia and da Cunha, Claudio Leinig Pereira and Bandeira, Antonio Milton},
title = {Validation of the Friedewald Formula in Patients with Metabolic Syndrome},
journal = {Cholesterol},
year = {2014},
volume = {2014},
pages = {1--5},
doi = {10.1155/2014/261878}
}
EUVIMED